EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte Studie

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study

Xu Yao, Yi Liu, Yang Luo, Xiaochun Liu, Min Zhou, Bin Yang iD, Lunfei Liu, Linfeng Li, Weijun Liu, Xiaoyong Man iD, Aijun Chen, Yuling Shi iD und 6 weitere

British Journal of Dermatology · 2026

DOI: 10.1093/bjd/ljag092 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Xu Yao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chine…. Hauptthemen laut MEDLINE: Chronic Urticaria, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Hangzhou Highlight Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic spontaneous urticaria (CSU) places a considerable burden on both patients and caregivers. Current treatments for CSU are inadequate for some patients. TLL-018, an oral tyrosine kinase 2/Janus kinase 1 (TYK2/JAK1) inhibitor, is currently being investigated as a potential treatment for CSU.

Objectives

To evaluate the efficacy and safety of TLL-018 for treating moderate-to-severe CSU in patients with an inadequate response to antihistamines.

Methods

In this multicentre, double-blind, randomized, placebo-controlled, parallel-group pilot study (NCT05373355), patients with CSU who showed an inadequate response to antihistamines were given (1: 1: 1) 10 or 30 mg of TLL-018, or placebo, orally twice daily. After 4 weeks, patients on placebo were switched to TLL-018 20 mg and continued treatment for a further 8 weeks. The primary endpoint was safety, while secondary endpoints included efficacy measures, such as weekly Urticaria Activity Score (UAS7) ≤ 6, UAS7 = 0, and a Dermatology Life Quality Index score of 0 or 1, at weeks 4 and 12.

Results

Overall, 41 patients were randomly assigned to TLL-018 10 mg (n = 14), 30 mg (n = 13) or placebo (n = 14). At week 4, the placebo-adjusted change from baseline (analysed using Ancova) in UAS7, weekly Itch Severity Score and weekly Hive Severity Score was –11.5, –8.0 and –3.8, respectively, in the 10-mg TLL-018 group, and –16.0, –9.0 and –7.0, respectively, in the 30-mg group. At week 12, the proportions of patients achieving UAS7 ≤ 6 and UAS7 = 0 were 54% and 39%, respectively, in the placebo-then-20-mg group, 71% and 64% in the 10-mg group, and 62% and 54% in the 30-mg group. Common treatment-emergent adverse events included elevated serum creatine kinase and blood lipid levels, hyperglycaemia and urinary occult blood.

Conclusions

TLL-018 was well tolerated and effective in treating moderate-to-severe CSU in patients who had an inadequate response to antihistamines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaProtein Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodHistamine H1 AntagonistsPilot ProjectsSeverity of Illness IndexTreatment OutcomePyrroles

Substanzen

delgocitinibHistamine H1 AntagonistsProtein Kinase InhibitorsPyrroles

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanji…
  • Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China.
  • Dermatology Hospital of Southern Medical University, Guangzhou, China.
  • The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
  • Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Dermatology Hospital of Jiangxi Province, Nanchang, China.

ORCID-Profile: Bin Yang, Xiaoyong Man, Yuling Shi, Juan Tao, Qianjin Lu

Förderung

  • Hangzhou Highlight Pharmaceutical Co., Ltd.

Zitieren

APA

Yao, X., Liu, Y., Luo, Y., Liu, X., Zhou, M., Yang, B., Liu, L., Li, L., Liu, W., Man, X., Chen, A., Shi, Y., Ding, Y., Sun, Q., Tao, J., Chen, J., Liang, C., & Lu, Q. (2026). Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag092

Vancouver

Yao X, Liu Y, Luo Y, Liu X, Zhou M, Yang B, et al. Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag092

BibTeX
@article{Yao2026,
  author = {Yao, Xu and Liu, Yi and Luo, Yang and Liu, Xiaochun and Zhou, Min and Yang, Bin and Liu, Lunfei and Li, Linfeng and Liu, Weijun and Man, Xiaoyong and Chen, Aijun and Shi, Yuling and Ding, Yangfeng and Sun, Qing and Tao, Juan and Chen, Jingjing and Liang, Congxin and Lu, Qianjin},
  title = {Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag092}
}
Kostenlos starten →